ReviewPostepy dermatologii i alergologii2014
Cardiovascular safety of antihistamines.
Review in Postepy dermatologii i alergologii, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 50 citations in OpenAlex.
- Cardiac Safety of Intranasal Chlorpheniramine: An Exposure-Based Risk Assessment.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Antihistamine drug terfenadine suppressed the cycle progression of gastric cancer cells by targeting PI3K/AKT/mTOR signaling.Frontiers in pharmacology · 2026Article
- Anti-vasospastic mast cell stabilizers: a novel therapeutic approach to anaphylaxis-induced acute coronary syndrome.Clinical and experimental vaccine research · 2025Article
- Astemizole Exacerbates 5-Fluorouracil-Triggered Cardiotoxicity by Enhancing Ptgs2.Cardiovascular toxicology · 2025Article
- Review
- Quantitative Structure-Activity Relationship Models to Predict Cardiac Adverse Effects.Chemical research in toxicology · 2024Article
- Association of Cardiovascular Disease and Chronic Spontaneous Urticaria: A Case-Control Study.American journal of clinical dermatology · 2024Article
- Astemizole, a Second-Generation Histamine H1-Receptor Antagonist, Did Not Attenuate the Aggregation Process of α-Synuclein In Vitro.Biomedicines · 2024Article
- Safety of hydroxyzine in the sedation of pediatric dental patients.Journal of dental anesthesia and pain medicine · 2022Review
- Repurposing drugs as COVID-19 therapies: A toxicity evaluation.Drug discovery today · 2022Review
- Insights into urticaria in pediatric and adult populations and its management with fexofenadine hydrochloride.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2022Review
- Cardiac Manifestations in Patients with COVID-19: A Scoping Review.Global heart · 2022Article
- Oral sedation in dentistry: evaluation of professional practice of oral hydroxyzine in the University Hospital of Rennes, France.European archives of paediatric dentistry : official journal of the European Academy of Paediatric Dentistry · 2021Article
- Structure-Based Prediction of hERG-Related Cardiotoxicity: A Benchmark Study.Journal of chemical information and modeling · 2021Article
- Turkish Guideline for Diagnosis and Treatment of Allergic Rhinitis (ART).Turkish archives of otorhinolaryngology · 2021Article
- Cough Remedies for Children and Adolescents: Current and Future Perspectives.Paediatric drugs · 2020Article
- Measurement and Management of QT Interval Prolongation for General Physicians.Journal of general internal medicine · 2020Review
- Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to success.Breast cancer research and treatment · 2019Review
- Using Patient Profiles To Guide The Choice Of Antihistamines In The Primary Care Setting In Malaysia: Expert Consensus And Recommendations.Therapeutics and clinical risk management · 2019Review
- Comprehensive review of cardiovascular toxicity of drugs and related agents.Medicinal research reviews · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Histamine is a mediator, which increases the permeability of capillaries during the early phase of allergic reaction, causes smooth muscle contraction of bronchi and stimulates mucous glands in the nasal cavity. Antihistamines are the basis of symptomatic treatment in the majority of allergic diseases, especially allergic rhinitis, allergic conjunctivitis, urticaria and anaphylaxis. The cardiotoxic effects of the two withdrawn drugs, terfenadine and astemizole, were manifested by prolonged QT intervals and triggering torsades de pointes (TdP) caused by blockade of the 'rapid' I Kr potassium channels. These phenomena, however, are not a class effect. This review deals with a new generation of antihistamine drugs in the context of QT interval prolongation risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.